Anti-GPIIb-IIIa drugs: Current strategies and future directions

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 427-443

  Coller, B S ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Abciximab; Angioplasty; Anti thrombotic therapy; Eptibatide; Tirofiban; Unstable angina

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ARGATROBAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; LAMIFIBAN; LEPIRUDIN; LOTRAFIBAN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY LM 609; ORBOFIBAN; PLACEBO; RETEPLASE; SIBRAFIBAN; STREPTOKINASE; TENECTEPLASE; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; XEMILOFIBAN;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; AMINO ACID SEQUENCE; ARTERY DISEASE; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; FIBRINOLYTIC THERAPY; HUMAN; IMMUNITY; ISCHEMIA; MOLECULAR WEIGHT; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; RISK ASSESSMENT; SICKLE CELL ANEMIA; STENT; STROKE; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034918474     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616241     Document Type: Conference Paper

References (150)

1. Bindidng of abciximab to αVβ3 and activated αMβ2 receptors: With a review of platelet-leukocyte interactions
2. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
3. GPIIb/IIIa antagonists: Development of abciximab and pharmacology of select agents
4. Development of eptifibatide
5. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
6. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
7. Preclinical development of c7E3 Fab; A mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans
8. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins
9. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
10. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): Flow and endocytic mechanisms contribute to the transport
11. Accessibility of abciximab to megakaryocyts and endothelial cells in the bone marrow compartment: Studies on a patient receiving antithrombotic therapy
12. Intracellular trafficking of the alphaIIbbeta3 receptor antagonist, abciximab, in normal and Glanzmann's diseases megakaryocytes
13. High-dose abciximab during coronary angioplasty in a patient with essential thrombocytosis
14. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
15. Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys
16. Immunologic and biochemical characterization of homozygous and heterozygous Glanzmann's thrombasthenia in Iraqi-Jewish and Arab populations of Israel: Comparison of techniques for carrier detection
17. 2+ on GPIIb-IIIa interactions with integrilin: Enhanced GPIIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
18. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
19. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors
20. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp
21. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
22. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man
23. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
24. In vitro and in vivo studies on the metabolism of tirofiban
25. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition
26. Platelet glycoprotein IIb/IIIa receptor inhibitors
27. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
28. IIb's are not IIb's
29. Unexpected mortality reduction with abciximab for in-stent restenosis
30. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: Results of the EPISTENT (Evaluatin of Platelet IIb/IIIa Inhibitor for Stenting Trial) diabetic substudy
31. Abciximab reduces mortality in diabetics following percutaneous coronary intervention
32. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
33. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators
34. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction
35. Cost-effectiveness of cholesterol-lowering therapies according to selected patients characteristics
36. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention
37. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators
38. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
39. Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction
40. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa antagonism for the reduction of acute coronary syndrome events in a Global Organization Network
41. Images in cardiovascular medicine. Abciximab-associated pseudothrombocytopenia
42. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy
43. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group
44. Acute profound thrombocytopenia following c7E3 Fab (Abciximab) therapy: Case reports, review of the literature and implications for therapy
45. Thrombocytopenia induced by abciximab: Studies of pathogenesis
46. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia
47. Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists
48. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab
49. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier
50. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
51. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis of major clinical trials
52. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: A nemesis of platelet glycoprotein IIb/IIIa inhibitors
53. Clinical experience in coronary bypass surgery for abciximab-treated patients
54. Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials. Improve long-term outcome with abciximab GP IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibition in STENTing
55. Emergency coronary artery bypass graft surgery in abciximab-treated patients
56. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective
57. Coronary bypass surgery within 12 h of administration of abciximab remains safe despite an increased risk of perioperative bleeding
58. Efficacy of abciximab readministration in coronary intervention
59. Readministration of abciximab: Interim report of the ReoPro readministration registry
60. Abciximab readministration: A single-operator community-hospital experience
61. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. The ESPRIT investigators. Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy
62. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT trial investigators. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy
63. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation
64. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acut coronary syndromes
65. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
66. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT
67. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting
68. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrelin therapy
69. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: Results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study
70. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM study investigators. Platelet receptor inhibition in ischemic syndrome management
71. Benefit of tirofiban + heparin therapy in unstable angina/non-Q-wave myocardial infarction patients is observed regardless of interventional treatment strategy
72. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
73. Preoperative use of enoxaparin and tirofiban: Possible association with increased bleeding postbypass
74. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis"
75. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the prevention of ischemic complications trial
76. Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intevention
77. In vivo demonstration of an antithrombin effect of abciximab
78. Mechanisms of cellular activation by platelet microparticles
79. Platelets and thrombolytic therapy
80. Augmentation of thrombolysis with antiplatelet drugs. Overview
81. Cardioprotective effects of abciximab (ReoPro) in an isolated perfused rat heart model of ischemia and reperfusion
82. Minimal myocardial damage during coronary intervention is associated with impaired outcome
83. Long-term clinical events following creatine kinase - Myocardial band isoenzyme elevation after succesful coronary stenting
84. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
85. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial
86. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy
87. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
88. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty
89. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction
90. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
91. CD40-CD40 ligand
92. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease
93. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes
94. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
95. Agonist-activated alphavbeta3 on platelets and lymphocytes binds to the matrix protein osteopontin
96. The activation state of alphavbeta3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin
97. Inhibition of vascular smooth muscle cell adhesion and migration by c7E3 fab (abciximab): A possible mechanism for influencing restenosis
98. Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: Potential contributing mechanism of benefit in acute coronary syndromes
99. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction
100. Tirofiban, eptifibatide, but not abciximab, leukocyte-platelet interactions
101. Monitoring platelet GPIIb/IIIa antagonist therapy
102. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100)
103. A quick simple method of determining platelet aggregability following glycoprotein IIb/IIIa receptor inhibitor administration
104. Efficacy of abciximab induced platelet blockade using a rapid point of care assay
105. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus
106. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: Continuous platelet inhibition by the combination of abciximab and ticlopidine
107. The rapid platelet function assay (RPFA): An automated and quantitative cartridge-based method
108. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event following percutaneous coronary intervention. Results of the GOLD (Au-Assessing Ultegra) multicenter study
109. Unstable angina: PARAGON, PURSUIT, PRISM, and PRISM-Plus
110. Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: Rationale and design of the PARAGON B study. The PARAGON B International Steering Committee
111. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary PTCA organization and randomized trial (RAPPORT) investigators
112. Abciximab associated with primary angioplasty and stenting in acute myocardial infarction: The ADMIRAL study
113. Abciximab facilitates the rate of extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 investigators
114. Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14
115. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group
116. The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: Current practice and future trends
117. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) trial
118. The TETAMI Trial: The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolyzed: Methods and design
119. Platelet glycoprotein IIb/IIIa receptor antagonist used in conjunction with thrombolysis for peripheral arterial thrombosis
120. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study. The Abciximab in Ischemic Stroke Investigators
121. Fatal hemorrhagic transformation of acute cerebral infarction after the use of abciximab
122. Basilar artery rethrombosis: Successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor
123. The platelet IIb/IIIa inhibitor abciximab as adjunctive therapy in carotid stenting of potential thrombotic lesions
124. Incomplete resolution of basilar artery occlusion after intra-arterial thrombolysis: Abciximab and heparin prevent early rethrombosis
125. Abciximab rescue in acute carotid stent thrombosis
126. Abciximab in carotid stenting for postsurgical carotid restenosis: Intermediate results
127. Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin
128. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT
129. Heparin-induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA - Treatment with lepirudin (Refludan) and abciximab (Reo pro) during recanalization of the RCA
130. Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease
131. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab, ReoPro™)
132. Blockade of GPIIb/IIIa inhibits the release of vascular endothelial growth factor (VEGF) from tumor cell-activated platelets and experimental metastasis
133. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo
134. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications
135. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
136. Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induce by platelet-activating factor
137. Platelets, coagulation, and fibrinolysis in sickle cell disease: Their possible role in vascular occlusion
138. Glyco-protein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons
139. Glycoprotein IIb/IIIa receptor inhibitor attenuates platelet aggregation induced by thromboxane A2 during in vitro nonpulsatile ventricular assist circulation
140. 2, a monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of Escherichia coli
141. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization EXCITE trial investigators. Evaluation of oral xemilofiban in controlling thrombotic events
142. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial
143. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. The SYMPHONY Investigators. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes
144. Increased mortality with oral glycoprotein IIb/IIIa antagonists
145. Evidence of platelet activation during treatment with GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
146. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction
147. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation
148. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus thrombolysis for occluded coronary arteries in patients with Acute Myocardial Infarction Study Investigators